Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCL

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.

Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.

Recent Videos
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
This series features 2 KOLs.
This series features 2 KOLs.
relapsed or refractory mantle cell lymphoma, glofitamab, Obinutuzumab, phase 1/2 study, NCT03075696, Tycel J. Phillips, MD
This series features 2 KOLs.
This series features 2 KOLs.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content
Creating Confidence While Climbing the Ranks in the Lymphoma Field

Creating Confidence While Climbing the Ranks in the Lymphoma Field

Ariana Pelosci
July 25th 2024
Article

“Sometimes you have to be a little more assertive and a little louder, and you have to step up to the front,” Julie M. Vose, MD, MBA, said.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

The drug developers of tabelecleucel are seeking approval of the treatment for patients with EBV-positive post-transplant lymphoproliferative disease.

BLA Accepted for Tabelecleucel in EBV+ Lymphoproliferative Disease

Roman Fabbricatore
July 18th 2024
Article

The drug developers of tabelecleucel are seeking approval of the treatment for patients with EBV-positive post-transplant lymphoproliferative disease.

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

Epcoritamab Approval Expands Bispecific Use in Follicular Lymphoma

Tycel Phillips, MD
July 8th 2024
Podcast

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

Data from a phase 1/2 trial support the potential clinical activity of DSP-5336 in patients with relapsed/refractory AML harboring a KMT2A rearrangement.

DSP-5336 Earns FDA Fast Track Status in R/R KMT2A+ Acute Myeloid Leukemia

Russ Conroy
July 16th 2024
Article

Data from a phase 1/2 trial support the potential clinical activity of DSP-5336 in patients with relapsed/refractory AML harboring a KMT2A rearrangement.

FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma

FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma

ONCOLOGY Staff
July 12th 2024
Article

Michael Wang, MD, spoke about the recent liso-cel approval in mantle cell lymphoma and the TRANSCEND trial.